IRTC iRhythm
Price Chart
Executive Summary
iRhythm (IRTC) presented new real-world data at HRS 2026 showing that 26% of atrial fibrillation (AF) recurrences after ablation and 60% of clinically significant arrhythmias in pregnant patients are missed with standard 24–48-hour Holter monitoring, reinforcing the clinical advantage of its 14-day Zio ambulatory ECG monitoring. The findings support broader adoption of extended monitoring to improve diagnosis, anticoagulation decisions, and maternal care.
Actionable Insight
These data strengthen iRhythm’s clinical differentiation and could accelerate adoption in high-value settings like post-ablation monitoring and prenatal cardiology. Traders should monitor for follow-up publications, payer coverage changes, or new clinical guidelines incorporating extended monitoring, which could drive volume and revenue growth.
Key Facts
- 26% of AF recurrences after ablation were detected beyond 48 hours, meaning short-term monitoring would misclassify up to 1 in 4 patients as false negatives.
- 60% of clinically significant arrhythmias in pregnant patients were first detected after 48 hours, with 13.6% having such events.
- Study included 11,051 post-ablation patients and 486 pregnant women monitored via Zio devices.
- 99.2% median analyzable time in pregnancy study confirms high data quality with Zio monitoring.
- Data challenge clinical validity of trials like OCEAN that rely on 24–48-hour monitoring for anticoagulation decisions.
Financial Impact
Potential revenue upside from increased adoption in post-ablation and obstetric cardiology markets; no direct financial figures disclosed.
Risk Factors
- Market adoption may lag despite strong evidence due to entrenched use of Holter monitors.
- Reimbursement constraints for extended monitoring in pregnancy or post-ablation settings could limit commercial impact.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281593 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
8-K
| $109.00 awaiting T+5 | awaiting T+5 | — | $113.83 (+4.43%) |
|
May 28, 2026
12d ago
|
8-K
| $115.61 $107.35 | ▼ −7.14% | ▼ −7.46% | $113.83 (−1.54%) |
|
May 11, 2026
29d ago
|
144
| $118.31 $110.94 | ▼ −6.23% | ▼ −6.31% | $113.83 (−3.79%) |
|
May 4, 2026
5w ago
|
Insider Cluster
| $119.18 $116.84 | ▼ −1.96% | ▼ −4.90% | $113.83 (−4.49%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $120.80 $124.87 | ▲ +3.37% | ▲ +1.02% | $113.83 (−5.77%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $125.96 $119.18 | ▼ −5.38% | ▼ −5.78% | $113.83 (−9.63%) |
|
Apr 17, 2026
7w ago
|
DEFA14A
| $124.91 $125.96 | ▲ +0.84% | ▼ −0.07% | $113.83 (−8.87%) |
|
Feb 25, 2026
15w ago
|
Insider Cluster
| $135.90 $127.95 | ▲ +5.85% | ▲ +4.75% | $113.83 (+16.24%) |
|
Feb 25, 2026
15w ago
|
Insider Cluster
| $135.90 $127.95 | ▲ +5.85% | ▲ +4.75% | $113.83 (+16.24%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $137.10 $125.85 | ▲ +8.21% | ▲ +7.18% | $113.83 (+16.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access